CRISPR Therapeutics AG (CRSP) Change in Receivables (2016 - 2025)
CRISPR Therapeutics AG (CRSP) reported Change in Receivables of -$25.0 million for Q1 2025, up 87.5% on a YoY basis from -$13.3 million in Q1 2024, and down 200.0% sequentially from $25.0 million in Q4 2024.
CRISPR Therapeutics AG (CRSP) Change in Receivables (2016 - 2025) Analysis & Trends
CRISPR Therapeutics AG (CRSP) has 10 years of Change in Receivables data on file, last reported at -$25.0 million in Q1 2025.
- For the quarter ending Q1 2025, Change in Receivables rose 87.5% year-over-year to -$25.0 million; the trailing twelve-month figure through Dec 2025 stood at -$25.0 million (up 85.71% YoY), and the FY2025 full-year result was -$25.0 million, up 85.71% from the prior year.
- Change in Receivables fell to -$25.0 million in Q1 2025, from $25.0 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $200.0 million in Q4 2023 to a low of -$200.0 million in Q1 2024.
- A 5-year average of -$11076.9 and a median of -$17000.0 in 2022 frame the typical range for Change in Receivables.
- Peak annual rise in Change in Receivables reached 408263.27% in 2023, while the deepest fall reached 411664.71% in 2023.
- Tracing CRSP's Change in Receivables over 5 years: stood at $153000.0 in 2021, then plunged by 132.03% to -$49000.0 in 2022, then soared by 408263.27% to $200.0 million in 2023, then plunged by 87.5% to $25.0 million in 2024, then tumbled by 200.0% to -$25.0 million in 2025.
- Business Quant data shows CRSP's Change in Receivables at -$25.0 million in Q1 2025, $25.0 million in Q4 2024, and -$200.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CRISPR Therapeutics AG | 4.57 Bn | 2.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -25.00 Mn |
| Mar 31, 2025 | -25.00 Mn |
| Dec 31, 2024 | 25.00 Mn |
| Dec 31, 2024 | 25.00 Mn |
| Mar 31, 2024 | -200.00 Mn |
| Mar 31, 2024 | -200.00 Mn |
| Dec 31, 2023 | 200.00 Mn |
| Dec 31, 2023 | 200.00 Mn |
| Sep 30, 2023 | -70.00 Mn |
| Sep 30, 2023 | -70.00 Mn |
| Jun 30, 2023 | 70.00 Mn |
| Jun 30, 2023 | 70.00 Mn |
| Dec 31, 2022 | -49,000.00 |
| Dec 31, 2022 | -49,000.00 |
| Sep 30, 2022 | -17,000.00 |
| Sep 30, 2022 | -17,000.00 |
| Jun 30, 2022 | -77,000.00 |
| Jun 30, 2022 | -77,000.00 |
| Mar 31, 2022 | -162,000.00 |
| Mar 31, 2022 | -162,000.00 |